Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01326780 · ClinicalTrials.gov registry record · Phase 2
A Study of a New Drug Treatment for Acne
A Phase 2 study, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 2
- Development phase
- 431
- Enrollment target
NCT01326780: Completed Phase 2 study, sponsored by Bausch Health Americas.
NCT01326780 is a Phase 2 study that has completed, run by Bausch Health Americas. The registered enrollment target is 431 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (224% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01326780, a Phase 2 study, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 431 participants
- Enrollment target
Study Summary
A study to determine if three different doses of a new acne treatment are safe and better at reducing facial acne than a treatment without active ingredient.
Primary Outcome
Change in lesion counts between baseline and end of study
Interventions
- DRUG 1.2% JNJ 10229570-AAA
- DRUG 2.4% JNJ 10229570-AAA
- DRUG 3.6% JNJ 10229570-AAA
- OTHER Vehicle control
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 431 participants |
| Start Date | 2011-03-31 |
| Est. Completion | 2012-03-31 |
| Phase | Phase 2 |
What the finished NCT01326780 record still lists
NCT01326780 is an interventional study that assigns participants to a tested intervention. The registered 431 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (224% higher).
The record links to 0 conditions, and to 4 interventions - of which 1.2% JNJ 10229570-AAA is the first listed.
NCT01326780 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01326780 about?
NCT01326780 is a clinical study titled "A Study of a New Drug Treatment for Acne". A study to determine if three different doses of a new acne treatment are safe and better at reducing facial acne than a treatment without active ingredient.
What is the current status of trial NCT01326780?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 431 participants. The study started on 2011-03-31. Estimated completion is 2012-03-31.
What interventions are being tested in trial NCT01326780?
The interventions under investigation include: 1.2% JNJ 10229570-AAA (DRUG), 2.4% JNJ 10229570-AAA (DRUG), 3.6% JNJ 10229570-AAA (DRUG), Vehicle control (OTHER).
Who is sponsoring clinical trial NCT01326780?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01326780's enrollment target sits among peer trials
431 90th of 2000 higher than 1,911 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05128890 · 431 participants
Evaluation of Resection Techniques for Pancreatic Tumors
- NCT05271240 · 432 participants · Phase 3
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
- NCT05365815 · 432 participants · NA
Melanated Group Midwifery Care (MGMC)
- NCT05499507 · 432 participants · NA
The Path to Optimal Black Maternal Heart Health: Comparing Two CVD Risk Reduction Interventions (Change of HEART)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI